The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...